Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Abstract

This concise review article critically examines the recent medical literature regarding gamma glutamyl transferase (GGT) with a special emphasis on newly proposed indications for GGT use, including cardiovascular risk assessment.

GGT is a ubiquitous glycosylated protein embedded in the outer surface of cell membranes, which catalyzes the transfer of glutamyl groups from various substrates and plays a key role in the antioxidant/pro-oxidant balance. In the past, the enzyme was considered a non-specific liver test. Current evidence supports the role of GGT in the assessment of portal hypertension in cystic fibrosis, porto-sinusoidal vascular disease, malignant mesothelioma, and incident type 2 diabetes and as a biomarker of cardiometabolic risk and cardiovascular disease.

Several specific points including the use of GGT in hepatology as a sensitive but poorly specific test and the association of GGT with metabolic syndrome, nonalcoholic fatty liver disease and its fibrotic stages, cardiometabolic risk, chronic kidney disease, neurodegenerative disorders and dementia, idiopathic pulmonary arterial hypertension, and Corona Virus Disease 2019 (COVID-19) are addressed based on the most recent research in these fields. Putative mechanisms linking GGT with increased metabolic stress and the effects of various therapeutic interventions on GGT values are also discussed.

We conclude that GGT has evolved from an indiscriminate liver test and an index of alcohol consumption to a biomarker of cardiometabolic health. The proper interpretation of GGT values (i.e., of hepatic vs. extrahepatic origin) is deeply affected by the clinical and epidemiological context. We propose that GGT may be utilized in public health campaigns, in the research arena, and in clinical practice to identify those individuals who can benefit most from the proactive preventive and therapeutic approaches, given that they are at high cardiometabolic risk.

Keywords

Cardiometabolic risk / chronic kidney disease / COVID / incident type 2 diabetes / insulin resistance / liver fibrosis / metabolic syndrome / NAFLD / portal hypertension

References

[1] Lonardo A,Alswat KA.History of nonalcoholic fatty liver disease.Int J Mol Sci2020;21:5888 PMCID:PMC7460697

[2] Mantovani A,Petracca G.Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021;6:903-13

[3] Aragon G.When and how to evaluate mildly elevated liver enzymes in apparently healthy patients.Cleve Clin J Med2010;77:195-204

[4] Howell WL.The low incidence of myocardial infarction in patients with portal cirrhosis of the liver: a review of 639 cases of cirrhosis of the liver from 17,731 autopsies.Am Heart J1960;60:341-4

[5] Ikeda Y,Taniguchi N.Expression of an active glycosylated human gamma-glutamyl transpeptidase mutant that lacks a membrane anchor domain.Proc Natl Acad Sci U S A1995;92:126-30 PMCID:PMC42830

[6] Meyts E, Heisterkamp N, Groffen J. Cloning and nucleotide sequence of human gamma-glutamyl transpeptidase.Proc Natl Acad Sci U S A1988;85:8840-4 PMCID:PMC282602

[7] West MB,Wickham S.Novel insights into eukaryotic γ-glutamyltranspeptidase 1 from the crystal structure of the glutamate-bound human enzyme.J Biol Chem2013;288:31902-13 PMCID:PMC3814782

[8] West MB,Quinalty LM,Li C.Autocatalytic cleavage of human gamma-glutamyl transpeptidase is highly dependent on N-glycosylation at asparagine 95.J Biol Chem2011;286:28876-88 PMCID:PMC3190695

[9] Hanigan MH.Gamma-glutamyl transpeptidase: redox regulation and drug resistance.Adv Cancer Res2014;122:103-41 PMCID:PMC4388159

[10] Hanigan MH.Immunohistochemical detection of gamma-glutamyl transpeptidase in normal human tissue.J Histochem Cytochem1996;44:1101-8

[11] PetitClerc C,Bagrel D,Siest G.Kinetic properties of gamma-glutamyltransferase from human liver.Clin Chem1980;26:1688-93.

[12] Wickham S,Cook PF.Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes.Anal Biochem2011;414:208-14 PMCID:PMC3099546

[13] Lieberman MW,Shi ZZ.Growth retardation and cysteine deficiency in gamma-glutamyl transpeptidase-deficient mice.Proc Natl Acad Sci U S A1996;93:7923-6 PMCID:PMC38850

[14] Stark AA,Pagano DA.Glutathione metabolism by gamma-glutamyltranspeptidase leads to lipid peroxidation: characterization of the system and relevance to hepatocarcinogenesis.Carcinogenesis1993;14:183-9

[15] Dominici S,Lorenzini E.Gamma-glutamyltransferase-dependent prooxidant reactions: a factor in multiple processes.Biofactors2003;17:187-98

[16] Dominici S,Corti A,Pompella A.Prooxidant reactions promoted by soluble and cell-bound γ-glutamyltransferase activity. Gluthione transferases and gamma-glutamyl transpeptidases. Elsevier; 2005. pp. 484-501.

[17] Paolicchi A,Tonarelli P.Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation-a potential mechanism in atherosclerosis.J Investig Med1999;47:151-60.

[18] Koenig G.Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk.Dis Markers2015;2015:818570 PMCID:PMC4620378

[19] Whitfield JB.Gamma glutamyl transferase.Crit Rev Clin Lab Sci2001;38:263-355

[20] Neuman MG,Chertin L.Gamma glutamyl transferase - an underestimated marker for cardiovascular disease and the metabolic syndrome.J Pharm Pharm Sci2020;23:65-74

[21] Diehl AM,Ishak KG.Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury.Gastroenterology1988;95:1056-62.

[22] Rouillon JM & Hanslik B.Élevation isolee de la γ-GT. Société Nationale Française de Gastro-Entérologie https://www.snfge.org/download/file/fid/3373

[23] Kalas MA,Leon M,Surani S.Abnormal liver enzymes: A review for clinicians.World J Hepatol2021;13:1688-98 PMCID:PMC8637680

[24] Brennan PN,Tapper EB.Gamma-glutamyl transferase (γ-GT) - an old dog with new tricks?.Liver Int2022;42:9-15

[25] Cipolli M,Waters D.Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: a longitudinal prospective birth cohort study.J Cyst Fibros2020;19:455-9

[26] Görtzen J,Vonnahme M.γ-glutamyl transferase is an independent biomarker of splanchnic thrombosis in patients with myeloproliferative neoplasm.Medicine (Baltimore)2016;95:e3355 PMCID:PMC4902387

[27] Pugliese N,Lleo A.High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels.Liver Int2022;42:1692-5

[28] De Gottardi A,Schouten J.Porto-sinusoidal vascular disease: proposal and description of a novel entity.2019;4:399-411

[29] Foddis R,Bonotti A.Big and free fractions of gamma-glutamyltransferase: new diagnostic biomarkers for malignant mesothelioma?.Diagnostics (Basel)2022;12:311 PMCID:PMC8870979

[30] Greb D,Matter A,Lauk O.Prospective validation and extension of the multimodality prognostic score for the treatment allocation of pleural mesothelioma patients.Eur J Cardiothorac Surg2022;62:ezac085 PMCID:PMC9334788

[31] Lonardo A,Scaglioni F.Hepatic steatosis and insulin resistance: does etiology make a difference?.J Hepatol2006;44:190-6

[32] Ballestri S,Targher G.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.J Gastroenterol Hepatol2016;31:936-44

[33] Chen SC,Jhao JY,Tsao CK.Liver fat, hepatic enzymes, alkaline phosphatase and the risk of incident type 2 diabetes: a prospective study of 132,377 adults.Sci Rep2017;7:4649 PMCID:PMC5498613

[34] Klaassen G,Deetman NPE,Bakker SJL.Liver enzymes and the development of posttransplantation diabetes mellitus in renal transplant recipients.Transplant Direct2017;3:e208 PMCID:PMC5585424

[35] Lallukka S.Non-alcoholic fatty liver disease and risk of type 2 diabetes.Best Pract Res Clin Endocrinol Metab2016;30:385-95

[36] Arrese M,Barrera F,Valenti L.Insights into nonalcoholic fatty-liver disease heterogeneity.Semin Liver Dis2021;41:421-34 PMCID:PMC8492194

[37] Krawczyk M,Maier IB,Lammert F.The frequent adiponutrin (pnpla3) variant p.ile148met is associated with early liver injury: analysis of a german pediatric cohort.Gastroenterol Res Pract2015;2015:205079 PMCID:PMC4539481

[38] Zhao W,Liu J,Li J.The Dose-response relationship between gamma-glutamyl transferase and risk of diabetes mellitus using publicly available data: a longitudinal study in Japan.Int J Endocrinol2020;2020:5356498 PMCID:PMC7054786

[39] Hua S,Kizer JR.Association of liver enzymes with incident diabetes in US Hispanic/Latino adults.Diabet Med2021;38:e14522

[40] Park JY,Kim HS.Cumulative exposure to high γ-glutamyl transferase level and risk of diabetes: a nationwide population-based study.Endocrinol Metab (Seoul)2022;37:272-80 PMCID:PMC9081297

[41] Wang N,Pei D.Association of distinct γ-glutamyltransferase trajectories with incident hyperglycemia using latent class growth mixture modeling: a longitudinal cohort study of Chinese adults.Diabetes Res Clin Pract2022;190:109968

[42] Bertoli S,Vignati L.Metabolic correlates of subcutaneous and visceral abdominal fat measured by ultrasonography: a comparison with waist circumference.Nutr J2016;15:2 PMCID:PMC4702394

[43] Després JP.Is visceral obesity the cause of the metabolic syndrome?.Ann Med2006;38:52-63

[44] Chait A.Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease.Front Cardiovasc Med2020;7:22 PMCID:PMC7052117

[45] Chen LW,Shyu YC.Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: a community-based cross-sectional study.Kaohsiung J Med Sci2021;37:819-27

[46] Coccia F,Guarisco G.Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity.Endocrine2020;67:569-78

[47] Foschi FG,Giacomoni P.Bagnacavallo Study GroupIs there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?.Ann Hepatol2020;19:380-7

[48] Willis BH.Spectrum bias--why clinicians need to be cautious when applying diagnostic test studies.Fam Pract2008;25:390-6

[49] Kozakova M,Morizzo C.RISC InvestigatorsGamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk.J Hum Hypertens2021;35:334-42

[50] Zinterl I,Schipf S.Low cardiopulmonary fitness is associated with higher liver fat content and higher gamma-glutamyltransferase concentrations in the general population - “The Sedentary's Liver”.Liver Int2022;42:585-94

[51] Lonardo A.Perspectives of nonalcoholic fatty liver disease research: a personal point of view.Explor Med2020:1:85-107

[52] Lonardo A,Targher G.Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?.Metab Target Organ Damage2021;1:3.

[53] Lonardo A,Arrese M.Perspectives on precision medicine approaches to NAFLD diagnosis and management.Adv Ther2021;38:2130-58 PMCID:PMC8107169

[54] Pennisi G,Romero-Gomez M.Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.Aliment Pharmacol Ther2022;55:604-15

[55] Liu Z,Dai Y.Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study.Lipids Health Dis2022;21:55 PMCID:PMC9233377

[56] Guan L,Tian H.Prevalence and risk factors of metabolic-associated fatty liver disease during 2014-2018 from three cities of Liaoning Province: an epidemiological survey.BMJ Open2022;12:e047588 PMCID:PMC8860048

[57] Ndrepepa G.Gamma-glutamyl transferase and cardiovascular disease.Ann Transl Med2016;4:481 PMCID:PMC5233492

[58] Kunutsor SK,Kootstra-Ros JE,Dullaart RP.Circulating gamma glutamyltransferase and prediction of cardiovascular disease.Atherosclerosis2015;238:356-64

[59] Ndrepepa G,Schunkert H,Kastrati A.Gamma-glutamyl transferase and prognosis in patients with coronary artery disease.Clin Chim Acta2016;452:155-60

[60] Kim YG,Jeong JH.Metabolic syndrome, gamma-glutamyl transferase, and risk of sudden cardiac death.J Clin Med2022;11:1781 PMCID:PMC8999874

[61] Liu CF,Guo TM,Wei YJ.Liver enzymes and the risk of atrial fibrillation: a meta-analysis of prospective cohort studies.Genet Test Mol Biomarkers2019;23:865-70

[62] Dhingra R,Wang TJ,D'Agostino RB Sr.Serum gamma-glutamyl transferase and risk of heart failure in the community.Arterioscler Thromb Vasc Biol2010;30:1855-60 PMCID:PMC2924453

[63] Wannamethee SG,Shaper AG,Sattar N.Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men.Arterioscler Thromb Vasc Biol2012;32:830-5

[64] Wang Y,Jousilahti P.Serum γ-glutamyltransferase and the risk of heart failure in men and women in Finland.Heart2013;99:163-7

[65] Hong SH,Kim JA.Gamma-glutamyl transferase variability and the risk of hospitalisation for heart failure.Heart2020;106:1080-6

[66] Ndrepepa G,Kastrati A.Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease.Clin Chim Acta2018;476:130-8

[67] Bijnens EM,Thiery E.Serum gamma-glutamyl transferase, a marker of alcohol intake, is associated with telomere length and cardiometabolic risk in young adulthood.Sci Rep2021;11:12407 PMCID:PMC8196210

[68] Gansevoort RT,Hemmelgarn BR.Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.The Lancet2013;382:339-52

[69] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut2022;71:156-62

[70] Fan Y,Man C.Association of serum gamma-glutamyltransferase with chronic kidney disease risk: a meta-analysis.Free Radic Res2018;52:819-25

[71] Li J,Li W,Ghanbari HA.Oxidative stress and neurodegenerative disorders.Int J Mol Sci2013;14:24438-75 PMCID:PMC3876121

[72] Yoo D,Jung YJ,Shin CM.Serum gamma-glutamyltransferase activity and Parkinson’s disease risk in men and women.Sci Rep2020;10:1258 PMCID:PMC6985223

[73] Lee YB,Park S.Gamma-glutamyl transferase variability and risk of dementia: a nationwide study.Int J Geriatr Psychiatry2020;35:1105-14

[74] Tang Z,Zhang W.Association between gamma-glutamyl transferase and mild cognitive impairment in Chinese women.Front Aging Neurosci2021;13:630409 PMCID:PMC7902766

[75] Kunutsor SK,Burgess S.Genetically elevated gamma-glutamyltransferase and Alzheimer’s disease.Exp Gerontol2018;106:61-6 PMCID:PMC5915296

[76] Reis GS,Silveira AP.Oxidative-stress biomarkers in patients with pulmonary hypertension.Pulm Circ2013;3:856-61 PMCID:PMC4070836

[77] Lu GH,Li C.Prognostic value of gamma-glutamyltransferase in male patients with idiopathic pulmonary arterial hypertension.Front Cardiovasc Med2020;7:580908 PMCID:PMC7644547

[78] Yogeswaran A,Lund J.Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters.J Heart Lung Transplant2022;41:400-10

[79] Luo C,Wu C.Liver dysfunction in idiopathic pulmonary arterial hypertension: prevalence, characteristics and prognostic significance, a retrospective cohort study in China.BMJ Open2021;11:e045165 PMCID:PMC8424845

[80] Du J,Yu CH.Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.World J Gastroenterol2014;20:569-77 PMCID:PMC3923033

[81] Franzini M,Guarino D.γ-Glutamyltransferase fractions in obese subjects with type 2 diabetes: relation to insulin sensitivity and effects of bariatric surgery.Obes Surg2018;28:1363-71

[82] Lainé F,Loustaud-Ratti V.Study GroupMetabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: a randomized controlled study in 274 patients.Hepatology2017;65:465-74

[83] Ma Q,Shao C.Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease.BMC Gastroenterol2021;21:215 PMCID:PMC8112063

[84] Malik A,Malik MI.Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.Clin J Gastroenterol2021;14:1579-86

[85] Pastori D,Di Rocco A.Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis.Br J Clin Pharmacol2022;88:441-51 PMCID:PMC9290532

[86] Bertolini A,Bodewes FAJA.Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis.Hepatology2020;72:1864-72 PMCID:PMC7404414

[87] Alroomi M,Alsaber A.In-hospital mortality in SARS-CoV-2 stratified by gamma-glutamyl transferase levels.J Clin Lab Anal2022;36:e24291 PMCID:PMC8993645

[88] Liu J,Yang Q.The clinical implication of gamma-glutamyl transpeptidase in COVID-19.Liver Res2021;5:209-16 PMCID:PMC8464026

[89] Ponziani FR,Nesci A.“Gemelli against COVID-19” groupLiver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients.Aliment Pharmacol Ther2020;52:1060-8 PMCID:PMC7361563

[90] Wanner N,Badia-I-Mompel P.Molecular consequences of SARS-CoV-2 liver tropism.Nat Metab2022;4:310-9 PMCID:PMC8964418

[91] Hamming I,Bulthuis ML,Navis G.Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.J Pathol2004;203:631-7 PMCID:PMC7167720

[92] Bedogni G,Miglioli L.The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol2006;6:33 PMCID:PMC1636651

[93] Lonardo A,Bedogni G,Tiribelli C.The fatty liver index (FLI) 15 years later: a reappraisal.Metab Target Organ Damage2021;